Sermorelin/ GHRH 5mg For Sale
Ghrelin (also called Sermorelin) is a synthetic peptide that mimics the first 29 amino acids of the natural growth-hormone-releasing hormone (GH-RH). The hypothalamus secretes GHRH, instructing the anterior pituitary to release growth hormone (GH). This 29-amino-acid fragment contains the portion responsible for activating GH. It is more stable and easier to handle in laboratory studies compared to the full-length hormone, providing reproducible activity for research purposes. Sermorelin is produced under regulated lab conditions to ensure high purity and reproducibility. It is used in controlled in vitro experiments and in preclinical studies of growth-hormone signaling, pituitary function, and metabolism.
Sermorelin (GHRH 1-29) Molecular Structure and Chemical Properties
Sermorelin is a synthetic peptide containing 29 amino acids. Its sequence corresponds to the first 29 amino acids of naturally occurring human growth hormone-releasing hormone (GHRH), which contains 44 amino acids. Sermorelin retains the ability to bind to and activate GHRH receptors.
Sermorelin Chemical Properties Table
| Property | Correct Information |
| Compound Name | Sermorelin |
| Alternative Names | GHRH (1-29), GRF (1-29) |
| Molecular Formula | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Molecular Weight | 3,357.9 g/mol |
| CAS Number | 86168-78-7 |
| PubChem CID | 16132413 |
| Amino Acid Length | 29 amino acids |
| Peptide Classification | Synthetic polypeptide |
| One-Letter Sequence | YADAIFTNSYRKVLGQLSARKLLQDIMSR |
| C-Terminal Modification | Amidation (–NH₂) |
| Peptide Structure | Linear |
| Disulfide Bonds | None |
| Primary Receptor | GHRH receptor (GHRHR) |
| Research Focus | Growth hormone signaling and GHRH receptor activity |
The molecular formula, molecular weight, CAS number, and sequence match the
PubChem record for sermorelin.
Mechanism of Action
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary in laboratory models. This activates adenylate cyclase, raising intracellular cyclic AMP (cAMP) levels. Elevated cAMP enhances endogenous GH production while maintaining normal secretion patterns. Researchers can study the effects of increased natural GH on metabolism, protein synthesis, cell growth, and tissue repair without administering exogenous GH.
Research Applications
Sermorelin is used in laboratory research to examine GH release regulation and downstream effects on biological processes.
Growth Hormone Secretion Studies
Sermorelin stimulates GH release in cell cultures and isolated pituitary models. Dose-response, timing, and pulsatility are analyzed to reflect normal physiology, providing insight into GH regulation.
Pituitary Function Research
Sermorelin is applied to study pituitary responsiveness under various conditions, including age-related or stress-induced changes, helping to understand GH regulatory mechanisms.
Metabolic and Anti-Aging Research
In laboratory studies, Sermorelin is used to assess metabolism and age-related alterations. It influences protein turnover, lipid and glucose metabolism, and energy balance via endogenous GH and IGF-1 pathways, allowing mapping of GH-related metabolic regulation.
Preclinical Research Applications
Sermorelin is employed in approved animal studies for growth, tissue repair, bone density, and stress or injury recovery. These experiments allow evaluation of elevated endogenous GH without exogenous hormones.
Compound Form and Specification
Ghrelin / GH-RH (1-29) is supplied as a sterile glass vial containing 5 mg of white lyophilized powder. Purity exceeds 99% as confirmed by lab testing. No fillers, stabilizers, or preservatives are used, ensuring accurate dosing and reproducibility for laboratory and preclinical research.
Intended Research Use
This compound is intended exclusively for laboratory research. It can be used in controlled in vitro studies, including cell culture, and in approved preclinical animal models. Researchers use it to investigate GH signaling, pituitary function, and related metabolic processes. All handling must comply with institutional, ethical, and local regulations.
Storage and Handling
Store lyophilized powder at -20°C in a dry, dark environment. This preserves stability for long-term storage. After opening, minimize air exposure. Reconstitute using sterile or bacteriostatic water, mix gently without shaking, and store the solution at 2–8°C. Use within 14–30 days, depending on the solvent. For longer-term storage, subdivide into aliquots and freeze at -20°C or colder. Avoid repeated freeze-thaw cycles. Maintain aseptic techniques, wear gloves, and work in a clean, controlled environment to prevent contamination.
Regulatory and Safety Disclaimer
Sermorelin (GHRH 1-29) supplied by
Orion Peptides is intended strictly for laboratory research and scientific investigation. It is not intended for human or animal consumption, self-administration, diagnostic procedures, or therapeutic applications.
Research-grade Sermorelin sold by Orion Peptides is not an FDA-approved drug compound. Its safety, effectiveness, and suitability for clinical or personal use have not been established.
References
- Felix, A., et al. (1996). Human growth hormone-releasing hormone hGHRH(1-29)-NH₂: Systematic structure-activity relationship studies. Peptides, 17(4), 479–486.
- Rafferty, B., Poole, S., Clarke, R., & Schulster, D. (1985). Growth hormone-releasing factor analogue (hGRF1-29NH₂): Immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. Journal of Endocrinology, 107(3), R5–R8.
- Rivier, J., Rivier, C., Galyean, W., Yamamoto, G., & Vale, W. (1988). Potent long-acting growth hormone-releasing factor analogues. Annals of the New York Academy of Sciences, 527, 44–50.
- Esposito, P., et al. (2003). PEGylation of growth hormone-releasing hormone (GRF)(1-29) analogues. Journal of Endocrinology, 176(1), 87–95.
